Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs - Takeaways - MDSpire
Advertisement
Roswell Park Quick Talks: Breast Cancer and ADCs, Risk of Second HPV-Related Cancer, Cognitive Function and ICIs
Experts from Roswell Park Comprehensive Cancer Center will give remarks on racial and ethnic disparities in outcomes among people with metastatic breast cancer; risk patterns for second cancers associated with human papillomavirus (HPV); and effects of immune checkpoint inhibitors (ICI) on cognitive function.
Dr. Zunairah Shah presented findings on racial and ethnic disparities in outcomes for HER2-positive metastatic breast cancer treated with antibody-drug conjugates.
2
The study revealed that 83.7% of patients with metastatic HER2-positive breast cancer survived beyond 5 years with antibody-drug conjugates.
3
Dr. Pragati Gole Advani highlighted that survivors of HPV-associated cancers have a significantly higher risk of developing second HPV-related cancers.
4
The risk of second HPV-related cancers varies by first cancer site and sex, with female survivors at greater risk.
5
Dr. Song Yao's research indicated that cognitive function declines during the first year of immune checkpoint inhibitor treatment, especially in certain demographics.
